Premium
Cis‐platin and Methotrexate in the Treatment of Transitional Cell Carcinoma of the Urinary Tract
Author(s) -
CARMICHAEL J.,
CORNBLEET M. A.,
MacDOUGALL R. H.,
ALLAN S. G.,
DUNCAN W.,
CHISHOLM G. D.,
SMYTH J. F.
Publication year - 1985
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1985.tb06348.x
Subject(s) - methotrexate , urinary system , transitional cell carcinoma , medicine , oncology , urology , cancer , bladder cancer
Summary— Nineteen patients with recurrent or metastatic transitional cell carcinoma of the urinary tract were treated with a 3‐weekly combination of methotrexate 200 mg/m 2 as a 24‐h infusion with folinic acid rescue and cis‐platin 100 mg/m 2 . An objective response rate of 68% was obtained, with 4 patients (21 %) achieving complete remission. Pulmonary disease and lymph node metastases were particularly sensitive to this therapy. The median duration of response was 21 weeks with a median survival of 54 weeks in the responding patients. This regimen warrants further investigation in the treatment of invasive bladder carcinoma.